| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology/Experimental Medicine |
From INSERM U765 (F.Z., I.G.-F., A.M.F., C.B.-V.); INSERM U689 (J.-S.S., J.V.), Cardiovascular Research Center; INSERM U553 (F.F.-L., A.B.); Université Paris Denis Diderot (J.-S.S., F.F.-L., A.B., J.V.); INSERM U745 (I.B., I.L.), Laboratoire de Génétique Moléculaire; Université Paris Descartes (I.B., I.L., I.G.-F., A.M.F.), Faculté de Médecine; IFR 105 (F.F.-L., A.B.), Institut dHématologie; AP-HP (A.M.F.), Hôpital Européen Georges Pompidou, Service dHématologie Biologique, Paris, France.
Correspondence to Dr Catherine Boisson-Vidal, INSERM U765, Faculté de Pharmacie 4 av. de lObservatoire, 75270 Paris, France. E-mail catherine.boisson-vidal{at}univ-paris5.fr
Objectives— As SDF-1 and its cognate receptor CXCR4 play a key role in the survival and mobilization of immature cells, we examined whether preconditioning of endothelial progenitor cells (EPCs) with SDF-1 could further promote their capacity to enhance angiogenesis.
Methods and Results— EPC exposure to 100 ng/mL SDF-1 for 30 min induced a proangiogenic phenotype, with cell migration and differentiation into vascular cords in Matrigel and increased their therapeutic potential in a nude mouse model of hindlimb ischemia. This pretreatment enhanced EPC adhesion to activated endothelium in physiological conditions of blood flow by stimulating integrin-mediated EPCs binding to endothelial cells. Pretreated EPCs showed significantly upregulated surface
4 and
M integrin subunit expression involved in the homing of immature cells to a neovasculature and enhanced FGF-2 and promatrix metalloproteinase (MMP)-2 secretion. All these effects were significantly attenuated by EPC incubation with AMD-3100, a CXCR4 antagonist, by prior HSPGs disruption and by HUVEC incubation with anti–intercellular adhesion molecule1 (ICAM-1) and anti–vascular cell adhesion molecule (VCAM) blocking antibodies. Pretreated EPCs adhered very rapidly (within minutes) and were resistant to shear stresses of up to 2500s–1.
Conclusions— SDF-1 pretreatment during EPC expansion stimulates EPC adhesion to endothelial cells and thus augments the efficiency of cell therapy for ischemic vascular diseases.
EPC exposure to SDF-1 for 30 min induced a proangiogenic phenotype, enhancing not only the ability of these cells to adhere to activated endothelium but also promoting tube formation, via integrin-, CXCR4-, and HSPGs-dependent mechanisms. Subsequently, SDF-1–treated EPCs displayed a marked therapeutic potential in a model of mice hindlimb ischemia.
Key Words: endothelial progenitor cells SDF-1 ischemia HSPGs adhesion
Related Article:
Arterioscler. Thromb. Vasc. Biol. 2008 28: 1034-1035.
This article has been cited by other articles:
![]() |
T. Zhao, D. Zhang, R. W. Millard, M. Ashraf, and Y. Wang Stem cell homing and angiomyogenesis in transplanted hearts are enhanced by combined intramyocardial SDF-1{alpha} delivery and endogenous cytokine signaling Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H976 - H986. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. C. Gurtner and E. Chang "Priming" Endothelial Progenitor Cells: A New Strategy to Improve Cell Based Therapeutics Arterioscler. Thromb. Vasc. Biol., June 1, 2008; 28(6): 1034 - 1035. [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |